Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ResMed Inc. (RMD) vs SP Funds S&P 500 Sharia Industry Exclusions ETF (SPUS) Price & Performance

ResMed Inc.Trade
SP Funds S&P 500 Sharia Industry Exclusions ETFTrade

Price performance (Past 24H)

Key statistics

ResMed Inc. vs SP Funds S&P 500 Sharia Industry Exclusions ETF — how do they compare? ResMed Inc. trades at $219.5 (market cap $31.89B), while SP Funds S&P 500 Sharia Industry Exclusions ETF trades at $58.52. The key difference: ResMed Inc. pays a 1.19% dividend while SP Funds S&P 500 Sharia Industry Exclusions ETF pays none, and SP Funds S&P 500 Sharia Industry Exclusions ETF is trading nearer its 52-week high, ResMed Inc. nearer its low. Which is the better fit depends on your goals.

RMDSPUS
Market Cap
$31.89B
Sector
HealthBroad Market / Factor
52-Week High
$283.28$59.51
52-Week Low
$182.82$46.65
Enterprise Value
$31.24B
Dividend Yield
1.19%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ResMed Inc.

ResMed (RMD) trades at $221.05, down 3.2% amid a bearish technical signal, though it holds above key support at $218. The company reported strong Q4 2026 results with EPS of $2.95 beating estimates, and revenue grew 9% to a record $1.5 billion. However, weaker fiscal 2027 revenue guidance has pressured the stock. Fundamentals remain solid with a 26.94% net income margin and robust cash flow from operations of $1.75 billion in 2025.

The outlook is mixed; strong profitability and consistent earnings beats support upside toward the $235.70 consensus price target, but near-term sentiment is cautious due to the soft sales forecast and ongoing legal investigations. Key risks include competitive pressures and execution on guidance. Institutional buying by firms like HSBC and Canada Pension Plan provides confidence in long-term value.

SP Funds S&P 500 Sharia Industry Exclusions ETF

SPUS trades at $58.72, down 0.53% on the day, with technical indicators showing a neutral to slightly bullish bias. The stock exhibits a narrow trading range with key support and resistance clustered around $58-$59. Recent corporate actions include small quarterly dividends, but key fundamental valuation and profitability ratios are not publicly reported, limiting traditional analysis. No major recent news or earnings data is available to drive sentiment.

The outlook for SPUS is clouded by a lack of accessible fundamental data, presenting a challenge for valuation. The primary opportunity lies in potential undiscovered value, while the significant risk is the inability to assess the company's financial health, earnings power, or competitive position, making it a speculative holding dependent on broader market trends.

Returns comparison

Trailing returns across standard periods

About ResMed Inc.

ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.

Read more on RMD

About SP Funds S&P 500 Sharia Industry Exclusions ETF

SPUS tracks a market-cap weighted index of S&P 500 stocks that adhere to Sharia law. It screens out companies involved in non-compliant business activities such as alcohol, tobacco, gambling, and conventional finance, as well as excluding sectors like Aerospace & Defense, and Data Processing. By focusing on low-leverage stocks, SPUS provides investors with a value-conscious, ethically-aligned exposure to a diversified portfolio of large-cap U.S. equities.

Read more on SPUS